



Important points case consideration III: Interventions in GUCH

Worakan Promphan, MD.FSCAI. Kanyalak Vithessonthi, MD.

Day 3:

Saturday: 12 December 2020

8.00-9.00 am


Worakan Promphan

Proctor: Abbott, Occlutech, Lifetech Scientific, Lepu Medical,

Venus Medtech

Kanyalak Vithessonthi

No disclosure





Congenital heart disease A lifelong chronic condition

2020 ESC Guidelines for the management of adult congenital heart disease (ACHD) (European Heart Journal 2020 - doi/10.1093/eurheartj/ehaa554)








Case 1


- 23-year-old male, thalassemia major, s/p splenectomy
- Regular blood transfusion monthly
- 2006 (11y): Hypertension
 - Long segment CoA (4-5 cm)
 - Aorto-aortic bypass, PTFE graft 22 mm
 - Uneventful post-op with normal BP and no medication








- Regular follow-up yearly: uneventful
- 2017 (23 y): New onset HT
 - Right arm 143/59 mmHg
 - Right leg 119/53 mmHg










23 years old, s/p aorto-aortic bypass for 11 years, recurrent HT, conduit stenosis with heavy calcification



Krit Makonkaewkayoon, Noppon Taksaudom, Tassaluck Tonghong, and CMU team



CoA AHA Recommendations

Significant native or recurrent aortic CoA

- 1. UE/LE resting peak-to-peak gradient >20 mm Hg or mean Doppler systolic gradient >20 mm Hg.
- 2. UE/LE gradient >10 mm Hg or meanDoppler gradient >10 mm Hg2.1 decreased LV systolic function or AR
 - 2.2 with collateral flow

Therapeutic					
I	B-NR	6. Surgical repair or catheter-based stenting is recommended for adults with hypertension and significant native or recurrent coarctation of the aorta. S4.2.6-1,S4.2.6-2,S4.2.6-8-S4.2.6-12			
1	C-EO	7. GDMT is recommended for treatment of hypertension in patients with coarctation of the aorta. S4.2.6-13			
IIb	B-NR	8. Balloon angioplasty for adults with native and recurrent coarctation of the aorta may be considered if stent placement is not feasible and surgical intervention is not an option. 54.2.6-14			

CoA **ESC** Recommendations

Recommendations	Class ^a	Level ^b
Repair of coarctation or re-coarctation (surgically or catheter based) is indicated in hypertensive patients ^c with an increased non-invasive gradient between upper and lower limbs confirmed with invasive measurement (peak-to-peak ≥20 mmHg) with preference for catheter treatment (stenting), when technically feasible.		С
Catheter treatment (stenting) should be considered in hypertensive patients ^c with >50% narrowing relative to the aortic diameter at the diaphragm, even if the invasive peak-to-peak gradient is <20 mmHg, when technically feasible.	lla	С
Catheter treatment (stenting) should be considered in normotensive patients ^c with an increased non-invasive gradient confirmed with invasive measurement (peak-to-peak ≥20 mmHg), when technically feasible.	lla	C
Catheter treatment (stenting) may be considered in normotensive patients ^c with ≥50% narrowing relative to the aortic diameter at the diaphragm, even if the invasive peak-to-peak gradient is <20 mmHg, when technically feasible.	IIb	С










23 years old, s/p aorto-aortic bypass for 11 years, recurrent HT, conduit stenosis with heavy calcification










23 years old, s/p aorto-aortic bypass for 11 years, recurrent HT, conduit stenosis with heavy calcification




Krit Makonkaewkayoon, Noppon Taksaudom, Tassaluck Tonghong, and CMU team












Krit Makonkaewkayoon, Noppon Taksaudom, Tassaluck Tonghong, and CMU team






23 years old, s/p aorto-aortic bypass for 11 years, recurrent HT, conduit stenosis with heavy calcification









Krit Makonkaewkayoon, Noppon Taksaudom, Tassaluck Tonghong, and CMU team









Krit Makonkaewkayoon, Noppon Taksaudom, Tassaluck Tonghong, and CMU team

Case 2

- 17-year-old female
- ToF
- 2003: RMBT shunt
- 2007: Closure VSD, TAP, clipping RMBT shunt
- 2017: Hemoptysis

- BP 110/70 mmHg, HR 72/min, SpO₂ 98%
- PMI 6ICS, MCL, no heave, no thrill
- Single S_2 , gr. 2/6 to and fro murmur at LUSB
- Normal breath sound




TTE

- No residual VSD
- RVOT aneurysm 40 mm
- PA trunk short and dilated,
 30 mm in diameter
- Huge LPA 25 mm, RPA was not well seen
- Free PR , TAPSE 18 mm
- mild to moderate MR





CCT+CMR



Disconnected the distal RPA and lobar branches
Distal RPA 2.9 mm, proximal RPA 13 mm, distance 20 mm
Normal LPA
Forward flow Right: Left lung = 1:32


RVOT dilated 34 x 37 mm RVEDVi 188.4 mL/m²


RVEF 62.8 %


Moderate PR, RF 40.1%, mild TR




RPA angiogram confirmed interrupted RPA



















Immediate post Pre-procedure










CCT follow-up (6 months post)

- Patent newly implanted stent, no intimal proliferation
- Distal RPA 8.8 mm, proximal RPA 17.6 mm.
- LPA 23.1 mm
- Forward flow Right: Left lung = 1:3.5
- RVEDVi 163.8 mL/m²
- Normal RV systolic function, RVEF 56 %
- Severe PR, regurgitation fraction 40.3 %, mild TR







Single ventricle physiology

- Unbalanced ventricle, large inlet-outlet VSD, straddling TV, windsock MV
- DORV, d-TGA
- Severe infundibular-valvular PS

2003 (7 yrs old): Bidirectional Glenn operation (BDG), leaving antegrade PS


- CVP 20-22 mmHg
- LAP 10-12 mmHg
- O₂sat 85% at FiO₂ 0.6
- Fontan index 3.9

(Fontan index = PVR+LVEDP/Qp+Qs)

2007 (11 yrs old): cardiac cath

- RPA 25/20 (23) mmHg
- RA sat 57.3%
- Ao sat 70.6%
- Qp:Qs 0.32, Rp:Rs 0.27

Plan: Conservative treatment








2014 (17 yrs old): Clinical right sided HF


- Mild puffy eyelids
- SpO₂ 70%
- PSM gr 3/6 at LMPSB
- SEM gr 3/6 at LUPSB
- Hepatomegaly
- Pitting edema 2+
















Systole Diastole




Coronal Axial




- Supero-inferior ventricle
- Large inlet VSD 4 cm
- Severe RA dilatation
- Biventricular dilatation
- LVEF 54.6%
- Mild impaired RV systolic function
- Severe TR, severe PS

CMR 2014





- Patent Glenn shunt
- Flow outward from RPA
- McGoon ratio 1.6, Nakata 294 mm²/m²
- Multiple venous collateral dilatation



- Single ventricle, severe PS, s/p bidirectional Glenn shunt at age 7 years
- Severe TR
- Inadequate atrial communication





At age 17 year (2014)

- Single ventricle, severe PS s/p bidirectional Glenn shunt at severe TR,
- inadequate atrial communication

Operation.

- TV Replacement: Perimount Magna Mitral 29 mm
- Atrial septectomy
- VVIR pacemaker implantation







s/p TVR: Magna (Bovine pericardial valve) 29 mm, atrial septectomy, VVIR at age 18 years (2014)

immediate post-op



1 year post-op



Medications: lasix, aldactone, enalapril, lanoxin, warfarin x 6 months, continue ASA







Unbalanced ventricle, large VSD, d-TGA, severe PS


- S/P BDG, leaving antegrade flow at age 7 years (2003)
- S/P TVR: Magna Bovine pericardial valve 29 mm, atrial septectomy, VVIR at age 18 years (2014) Baseline O_7 sat 75-85%

2018 (age 22 years):

- Atrial flutter → RFA, start warfarin
- Echo: bulging atrial septum, moderate TS, mean PG 8 mmHg, mild MR, good ventricular function
- cardiac catheterization for hemodynamic evaluation
 - Mean PA pressure 26 mmHg, Ao sat 76.1%













Cardiac Catheterization

	Pressure (mmHg)	O ₂ sat (%)		Pressure (mmHg)	O ₂ sat (%)
LSVC	34/18 (25)		LPA	32/20 (24)	
RA	20/12 (15)	69.9	LUPV	19/12 (16)	94
IVC	19/11 (15)		LLPV	21/13 (16)	93.3
RV	82/4 (15)		RUPV	17/12 (14)	95.7
MPA	34/19 (26)	78.8	RLPV	19/11 (15)	95.1
RPA	32/19 (25)	78.9	AO	86/48 (65)	76.1

Hb 17.4%, LVEDP 14 mmHg Qp;Qs 0.383, Rp/Rs 0.512, PVR 3.9 WU.m² Fontan index 3.82 McGoon 1.62, Nakata index 215

Estimated Fontan pressure 40 mmHg

Estimated Fontan Pressure 40 mmHg


TPG = PAP-LAP = 25-16 = 9 mmHg Qp:Qs 0.38, TPG 9 mmHg If Qp:Qs = $1 \rightarrow \text{est.TPG} = 24$ mmHg Estimated PAP at Qp:Qs 1 = LAP + est.TPG= 16 + 24 = 40 mmHg





Angiograms




























2020 (age 24 years):


- Progressive dyspnea
- FC III-IV, swelling,
- O₂sat 63-70% (room air)



Single ventricle, severe PS


- S/P BDG, leaving antegrade flow at age 7 years (2003)
- S/P TV Replacement: Magna Bovine pericardial valve @29mm, atrial septectomy, VVIR at age 18 years (2014)
- S/P RFA , S/P Pacemaker reimplantation at age 23 years (2019) Baseline $\mathrm{O}_2\mathrm{sat}$ 75%






















ECHO at age 24 years

- s/p Rt. Bidirectional Glenn shunt, leaving antegrade flow
- Dilated IVC and hepatic vein
- Marked dilated RA, predominant right to left shunt
- Severe tissue valve stenosis at TV position, mean PG 10 mmHg
- Windsock MV, with moderate MR, mean MV inflow PG 5 mmHg
- Severe subvalvular and valvular PS, PG 120 mmHg
- No AR
- Patent Glenn, Lt arch





Age 7 yr: BDG, leaving PS

Age 18 yr: TV replacement , atrial septectomy, VVIR

Age 22 yr Atrial flutter S/PRFA






WHAT'S NEXT???

How to manage this patient?





Special considerations and recommendations for intervention in univentricular heart (1)



Recommendations	Class	Level
It is recommended that adults with unoperated or palliated UVHs undergo careful evaluation in specialized centres, including multimodality imaging as well as invasive work-up to decide whether they may benefit from surgical or interventional procedures.	I	С
Only well-selected symptomatic cyanotic patients, after careful evaluation [low pulmonary vascular resistances, adequate function of the AV valve(s), preserved ventricular function], should be considered candidates for a Fontan circulation.	lla	С
Patients with increased pulmonary blood flow — unlikely at adult age — should be considered for PA banding or tightening of a previously placed band.	lla	С







- Transcatheter tricuspid valve-in-valve
- +/- balloon pulmonic valve





































Age 7 yr: BDG, leaving PS

Age 18 yr: TV replacement , atrial septectomy, VVIR

Age 22 yr Atrial flutter stp RFA













- Follow up
- O₂sat 79-83%
- FC II
- Plavix, ASA, Warfarin, Diuretics, Enalapril, Thyroxine, Sildenafil
































TOGETHER"









CASE 4: 16-year-old, male

Progressive dyspnea ~3 months

ToF

- Age 1½ yrs: RMBT shunt 5 mm
- Age 2 ½ yrs: Total correction (TAP with bovine pericardium monocusp)
- Age 7 yrs: PVR (Bovine 25 mm, Magna), LPA plasty by Gore-Tex, PDA closure and TV repair

LOSS TO F/U


Age 16 yrs:

- Progressive dyspnea, CHF
- CMR: Dilated RVOT, Severe PR, MPA 29.3 mm, RVEDVi 329.9 mL/m², RVEF 25%, LVEF 15.7%
- Rx CHF \rightarrow Refer





Age 9 years




This visit: Age 16 years






EKG: QRS duration 210 msec

















































TTE

- Dilated hepatic vein and IVC, RAE
- Very poor systolic function both ventricles, LVEF 24%
- Severe TR, atrial septum bulging to the left
- No MR
- Free PR



IMPRESSION

- ToF
- s/p Total correction with TAP at age 2½ years
- s/p Redo-PVR (Bovine 25 mm, Magna), LPA plasty by Gore-Tex, PDA closure and TV repair at age 7 year
- CHF, severe TR, severe PR, poor both ventricular function

What is the next plan?

Recommendations for intervention after repair of tetralogy of Fallot (1)



Recommendations	Class	Level
Pulmonary valve replacement is recommended in symptomatic patients with severe PR ^a and/or at least moderate RVOTO. ^b	ı	С
In patients with no native outflow tract, $^{\rm c}$ catheter intervention (TPVI) should be preferred if anatomically feasible.	l I	С
 Pulmonary valve replacement should be considered in asymptomatic patients with severe PR and/or RVOTO when one of the following criteria is present: Decrease in objective exercise capacity Progressive RV dilation to RVESVi ≥80 mL/m² and/or RVEDVi ≥160mL/m²d and/or progression of TR to at least moderate Progressive RV systolic dysfunction RVOTO with RVSP >80 mmHg. 	lla	С

^aRegurgitant fraction by CMR >30–40%. - ^bPeak velocity >3 m/s - ^cPatients with previous RVOT surgery using homografts, bovine jugular vein grafts, bioprostheses/conduits - ^dConfirmed by repeated measurements.

Recommendations for intervention after repair of tetralogy of Fallot (2)



Recommendations	Class	Level
VSD closure should be considered in patients with residual VSD and significant LV volume overload or if the patient is undergoing pulmonary valve surgery.	lla	С
In patients with sustained VT who are undergoing surgical pulmonary valve replacement or transcutaneous valve insertion, pre-operative catheter mapping and transsection of VT-related anatomical isthmuses before or during the intervention should be considered.	lla	С
Electrophysiologic evaluation, including programmed electrical stimulation, should be considered for risk stratification for SCD in patients with additional risk factors (LV/RV dysfunction; non-sustained, symptomatic VT; QRS duration ≥180 ms, extensive RV scarring on CMR).	lla	С



PLAN


- Intervention
 - IABP
 - Transcatheter pulmonic valve-in-valve



























Post Pulmonic Valve-in-Valve (PViV)


- Off IABP
- On low dose inotrope 2 days
- Medications: Plavix, ASA, Diuretics, ARB, Lanoxin



















































Immediate post PViV




1 month post PViV











Age 2 1/2 yr: Total correction with TAP

Age 7 yr: Redo-PVR (Bovine 25 mm, Magna),

LPA plasty by Gortex, PDA closure, TV repair

Age 16 yr Transcatheter Pulmonic ViV, SAPIEN3 SIZE 26 MM

Severe TR, poor both cardiac function

WHAT'S NEXT???

What is the next plan?















THANK YOU